CAS 1637443-98-1

Formula: C34H43N7O2

InChI: InChI=1S/C34H43N7O2/c1-4-40(5-2)24-25-43-27-16-14-26(15-17-27)35-33-29-11-7-9-13-31(29)37-34(38-33)28-10-6-8-12-30(28)36-32(42)18-19-41-22-20-39(3)21-23-41/h6-17H,4-5,18-25H2,1-3H3,(H,36,42)(H,35,37,38)

InChI key: VIBJAHJNWHZSJP-UHFFFAOYSA-N

SMILES: CCN(CC)CCOC1=CC=C(C=C1)NC2=NC(=NC3=CC=CC=C32)C4=CC=CC=C4NC(=O)CCN5CCN(CC5)C

hVEGF-IN-1

CAS: 1637443-98-1

Formula: C₃₄H₄₃N₇O₂

Purity: 99%

Molecular weight: 581.7509

Ref: IN-DA01DUA9

hVEGF-IN-1

CAS: 1637443-98-1

hVEGF-IN-1

Formula: C₃₄H₄₃N₇O₂

Purity: ≥98%

Molecular weight: 581.75

Ref: 54-BUP12895

hVEGF-IN-1

CAS: 1637443-98-1

hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.

Formula: C₃₄H₄₃N₇O₂

Purity: 99.76% - >99.99%

Color and Shape: Solid

Molecular weight: 581.75

Ref: TM-T4288

hVEGF-IN-1

CAS: 1637443-98-1

N-(2-(4-((4-(2-(Diethylamino)ethoxy)phenyl)amino)quinazolin-2-yl)phenyl)-3-(4-methylpiperazin-1-yl)propanamide

Formula: C₃₄H₄₃N₇O₂

Purity: 99%

Molecular weight: 581.75

Ref: IN-DG00790184

hVEGF-IN-1

Controlled Product

CAS: 1637443-98-1

hVEGF-IN-1 is a recombinant human vascular endothelial growth factor (VEGF) that has been shown to be effective in the treatment of diabetic nephropathy. It acts by binding to VEGF receptors on the surface of cells, which triggers an intracellular signalling cascade that leads to increased blood flow and angiogenesis. hVEGF-IN-1 has also been shown to inhibit tnf-α, p-akt, and transcriptional activity in cultured human endothelial cells. This drug has been shown to have a significant inhibitory effect on inflammation by suppressing the expression of proinflammatory cytokines such as IL-6 and TNF-α. hVEGF-IN-1 may also decrease apoptosis and cell death induced by high glucose levels.

Formula: C₃₄H₄₃N₇O₂

Purity: Min. 95%

Molecular weight: 581.75 g/mol

Ref: 3D-MQC44398